Eli lilly’s retatrutide delivers up to 30% weight loss in phase 3 trial

Clears major obesity endpoints at 80 weeks

Eli Lilly appoints Chandan S. as Senior Director for Data Science and AI Engineering

AI and analytics leader brings extensive expertise in machine learning, GenAI, and life sciences decision intelligence to Lilly’s data science operations

Lilly's retatrutide delivers 30% weight loss in Phase 3 TRIUMPH-1 trial

All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks

Lilly and UNICEF launch $50M push to reach 30 million children with life-saving health care

The target reach is of more than 30 million young people and caregivers across 21 countries

Roche wins CE mark for Alzheimer’s blood test that could transform early diagnosis

The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline

Eli Lilly launches Lormalzi for early Alzheimer’s treatment in India

Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence

Lilly’s Omvoh shows rare long-term remission milestone in ulcerative colitis

Eli Lilly unveils $4.5 bn Indiana expansion

The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies

Lilly posts explosive Q1 2026 results

Lifts full-year outlook as obesity drug boom accelerates

Lilly buys Ajax Therapeutics for up to $2.3 billion to target rare blood cancers

Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026